High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Jonsson, Liv ^a   Gaber, Alexander ^a   Ulmert, David ^a   Uhlén, Mathias ^b,c   Bjartell, Anders ^a   Jirström, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Immunohistochemistry; Prognosis; Prostate cancer; RBM3

Indexed keywords

RBM3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

AGED; ARTICLE; BIOSYNTHESIS; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR; TISSUE MICROARRAY; TUMOR RECURRENCE;

AGED; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; RNA-BINDING PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053380290     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-91     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46(4):765-781. 10.1016/j.ejca.2009.12.014, 20116997.
3. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364(18):1708-1717. 10.1056/NEJMoa1011967, 21542742.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597. 10.1001/jama.281.17.1591, 10235151.
5. Bjartell A, Montironi R, Berney DM, Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011, 50(Suppl 1):76-84.
6. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011, 50(Suppl 1):61-75.
7. Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, Matsuda T, Fujita J. Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun 1997, 236(3):804-807. 10.1006/bbrc.1997.7059, 9245737.
8. Lleonart ME. A new generation of proto-oncogenes: cold-inducible RNA binding proteins. Biochim Biophys Acta 2010, 1805(1):43-52.
9. Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, et al. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 2008, 27(33):4544-4556. 10.1038/onc.2008.97, 2677646, 18427544.
10. Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Buhrer C. The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res 2010, 67(1):35-41. 10.1203/PDR.0b013e3181c13326, 19770690.
11. Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S, et al. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol 2009, 22(12):1564-1574. 10.1038/modpathol.2009.124, 19734850.
12. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005, 4(12):1920-1932. 10.1074/mcp.M500279-MCP200, 16127175.
13. Bjorling E, Lindskog C, Oksvold P, Linne J, Kampf C, Hober S, Uhlen M, Ponten F. A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2008, 7(5):825-844. 10.1074/mcp.M700411-MCP200, 17913849.
14. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas--a tool for pathology. J Pathol 2008, 216(4):387-393. 10.1002/path.2440, 18853439.
15. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 2010, 8:78. 10.1186/1479-5876-8-78, 2936876, 20727170.
16. Jonsson L, Bergman J, Nodin B, Manjer J, Ponten F, Uhlen M, Jirstrom K. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmo Diet and Cancer Study. J Transl Med 2011, 9(1):114. 10.1186/1479-5876-9-114, 3156749, 21777469.
17. Ehlen O, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K. RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. Transl Oncol 2011, 4(4):212-221. 3140008, 21804916.
18. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007, 177(2):540-545. 10.1016/j.juro.2006.10.097, 17222629.
19. Zeng Y, Kulkarni P, Inoue T, Getzenberg RH. Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem 2009, 107(1):179-188. 10.1002/jcb.22114, 19277990.
20. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23(3):609-618.
21. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J. DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl 2007, 30(4):282-291. discussion 291, 10.1111/j.1365-2605.2007.00772.x, 17573848.
22. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434(7035):864-870. 10.1038/nature03482, 15829956.
23. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434(7035):907-913. 10.1038/nature03485, 15829965.